

**Request under Freedom of Information Act 2000**

Thank you for your request for information which we received on 05 September 2019.

I am pleased to confirm the following.

**Question 1a**

**Does your trust treat advanced breast cancer ?**

Yes

**Question 1b**

**If none, where are your patients referred?**

N/A

**Question 2**

**In the past 3 months, how many advanced breast cancer patients [Stage IV] have the status of;**

We are unable to extract this data within this time frame

HR+ and HER2+ [Hormone receptor-positive and human epidermal growth factor 2-positive]	
HR+ and HER2- [Hormone receptor-positive and human epidermal growth factor 2-negative]	
HR- and HER2+ [Hormone receptor-negative and human epidermal growth factor 2-positive]	
HR- and HER2- [Hormone receptor-negative and human epidermal growth factor 2-negative] - Triple negative disease	
Not Known	

**Question 3**

**In the past 3 months, how many breast cancer patients were treated with:  
Abemaciclib (Verzenios) + aromatase inhibitor \***

**Abemaciclib (Verzenios) + Fulvestrant (Faslodex)**  
**Alpelisib (Piqray) + Fulvestrant (Faslodex)**  
**Atezolizumab (Tecentriq)\*\***  
**Bevacizumab (Avastin)**  
**Eribulin (Halaven)**  
**Everolimus (Afinitor) + Exemestane**  
**Fulvestrant (Faslodex) as a single agent**  
**Gemcitabine + paclitaxel**  
**Lapatinib (Tyverb)**  
**Neratinib (Nerlynx)**  
**Olaparib (Lynparza)**  
**Palbociclib (Ibrance) + aromatase inhibitor\***  
**Pertuzumab (Perjeta) + trastuzumab + docetaxel**  
**Ribociclib (Kisqali) + aromatase inhibitor\***  
**Ribociclib (Kisqali) + Fulvestrant (Faslodex)**  
**Talazoparib (Talzenna)**  
**Trastuzumab + paclitaxel**  
**Trastuzumab as a single agent**  
**Trastuzumab emtansine (Kadcyla)**

**Other active systemic anti-cancer therapy \*\***

**\*aromatase inhibitor eg. Anastrozole, Exemestane or Letrozole**

**\*\*eg. docetaxel, vinorelbine or capecitabine as a single agent**

Please see attached table for Question 3.

You are advised that this information is provided in accordance with the Freedom of Information Act 2000 and is for your personal use. Any re-use of this information will be subject to copyright and the Re-Use of Public Sector Information Regulations (1st July 05) and authorisation from Milton Keynes Hospital NHS Foundation Trust will be required. In the event of any re-use, the information must be reproduced accurately and not used in a misleading manner.

If you are unhappy with the information received in response to this request, please address your complaint to the Patient Affairs Office at Milton Keynes Hospital NHS Foundation Trust, Standing Way, Eaglestone, Milton Keynes MK6 5LD. If, after exhausting our internal process, you are still unhappy with the information received, you may write to the Information Commissioner's Office, Wycliffe House, Water Lane,

Wilmslow, Cheshire SK9 5AF.

If you need any further assistance, please do not hesitate to contact us at the address above.

Yours sincerely,

Freedom Of Information Co-ordinator  
For and on behalf of Milton Keynes Hospital NHS Foundation Trust

Any re-use of this information will be subject to the  
'Re-use of Public Sector Information Regulations' and best practice.